Bone Therapeutics SA: The preliminary documents for the Extraordinary General Shareholder Meeting on 22 November 2019 have been made available
Gosselies, Belgium, 22 October 2019, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapies to address high unmet medical needs in orthopaedics and bone diseases, informs its shareholders and holders of warrants and convertible bonds of the Company that an extraordinary general shareholder meeting will be held on Friday 22 November 2019 at 10am CET, at the Company’s registered offices, rue Auguste Piccard 37, 6041 Gosselies, Belgium. If the attendance quorum is not reached at this extraordinary shareholders’ meeting, a second shareholders’ meeting will be convened and held on 12 December 2019 as of 10am CET, at rue Auguste Piccard 37, 6041 Gosselies.The notice for the meeting, including the agenda of the day as well as the motions to vote, is published today in the Belgian Official Gazette and La Libre Belgique.The documents and preliminary information concerning this meeting are being made available to the shareholders and can be consulted on the website of the Company: www.bonetherapeutics.com, under the section Investors / Shareholders meeting, in compliance with the applicable law and regulations.It is also possible to receive the documents without charge upon simple request by email to firstname.lastname@example.org or by telephone on +32 (0)71 12 10 00. The documents are also available at the Company’s headquarters: rue Auguste Piccard 37, 6041 Gosselies, Belgium.
About Bone TherapeuticsBone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy and an innovative biological product in later-stage clinical development across a number of disease areas, which target markets with large unmet medical needs and limited innovation.Bone Therapeutics’ core technology is based on its allogeneic cell therapy platform (ALLOB) which uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, cutting-edge manufacturing process.The Company’s ALLOB product pipeline includes a cell therapy product candidate that is expected to enter Phase II/III clinical development for the treatment of delayed-union fractures and a Phase II asset in patients undergoing a spinal fusion procedure. In addition, the Company is also developing an off-the-shelf protein solution, JTA-004, which is expected to enter Phase III development for the treatment of pain in knee osteoarthritis.Bone Therapeutics’ cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. Further information is available at www.bonetherapeutics.com.
ContactsBone Therapeutics SA
Thomas Lienard, Chief Executive Officer
Jean-Luc Vandebroek, Chief Financial Officer
Tel: +32 (0) 71 12 10 00
email@example.comInternational Media Enquiries:
Consilium Strategic Communications
Tel: +44 (0) 20 3709 5701
firstname.lastname@example.orgFor French Media and Investor Enquiries:
NewCap Investor Relations & Financial Communications
Pierre Laurent, Louis-Victor Delouvrier and Arthur Rouillé
Tel: + 33 (0)1 44 71 94 94
email@example.comCertain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors` current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person`s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.